PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Internal Medicine II, Feldkirch Academic Teaching Hospital, Feldkirch, Austria.\', \'Private University of the Principality of Liechtenstein, Triesen, Principality of Liechtenstein.\', \'Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria.\', \'Department of Internal Medicine I, Feldkirch Academic Teaching Hospital, Feldkirch, Austria.\', \'Medical Central Laboratories, Feldkirch, Austria.\', \'University of Zurich, Zurich, Switzerland.\', \'Onkozentrum Zürich, Swiss Tumour Immunology Institute, Zürich, Switzerland.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1111/bjh.17982
?:doi
?:hasPublicationType
?:journal
  • British journal of haematology
is ?:pmid of
?:pmid
?:pmid
  • 34872162
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.036
?:rankingScore_hIndex
  • 169
?:title
  • Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all